DRUGS & SUPPLEMENTS
Uricont TU uses
Warnings and Precautions, Central Nervous System Effects (5.5) 07/2015
1 INDICATIONS AND USAGE
Uricont TU 3% (oxybutynin) gel 3% is a muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see Clinical Studies (14) ].
Uricont TU 3% is a muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. (1)
2 DOSAGE AND ADMINISTRATION
The recommended dosage is three pumps of Uricont TU 3% (84 mg/day) applied once daily to clean, dry, intact skin on the abdomen, or upper arms/shoulders, or thighs. Apply immediately after actuating the dose. Application sites may be rotated to reduce the potential for local site reactions [see Adverse Reactions (6.1) ]. Uricont TU 3% is for topical application only and should not be ingested.
Wash hands immediately after product application. Patients should cover the application site with clothing after the gel has dried if direct skin-to-skin contact at the application site is anticipated [see Warnings and Precautions (5.3) ].
3 DOSAGE FORMS AND STRENGTHS
Uricont TU 3% is a homogeneous, colorless to slightly colored gel 3%.
Gel; 3% (3)
The use of Uricont TU 3% is contraindicated in patients with the following conditions:
5 WARNINGS AND PRECAUTIONS
5.1 Urinary Retention
Use Uricont TU 3% with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.
5.2 Use in Patients with Gastrointestinal Disorders
Use Uricont TU 3% with caution in patients with gastrointestinal obstructive disorders because of the risk of gastric retention.
Uricont TU 3%, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis or intestinal atony.
Uricont TU 3% should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs that can cause or exacerbate esophagitis.
5.3 Skin Transference
Transfer of Uricont TU to another person can occur when vigorous bare skin-to-skin contact is made with the application site. To minimize the potential transfer of Uricont TU from treated skin to another person, patients should cover the application site with clothing after the gel has dried if direct skin-to-skin contact at the application site is anticipated [see Clinical Pharmacology (12.3) ]. Patients should wash their hands immediately after application of Uricont TU 3%.
5.4 Flammable Gel
Uricont TU 3% is an alcohol-based gel and is therefore flammable. Avoid open fire or smoking until gel has dried.
5.5 Central Nervous System Effects
Drugs containing Uricont TU are associated with anticholinergic central nervous system effects. A variety of CNS anticholinergic effects have been reported, including headache, dizziness, somnolence, confusion and hallucinations . Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment. Advise patients not to drive or operate heavy machinery until they know how Uricont TU 3% affects them. If a patient experiences anticholinergic CNS effects, drug discontinuation should be considered.
5.6 Myasthenia Gravis
Administer Uricont TU 3% with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.
Angioedema requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oral Uricont TU. In the event of angioedema, Uricont TU containing product should be discontinued and appropriate therapy promptly provided.
5.8 Controlled Narrow-Angle Glaucoma
Administer Uricont TU 3% with caution in patients being treated for narrow-angle glaucoma.
6 ADVERSE REACTIONS
Most common adverse reactions are dry mouth, and application site reactions. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.
The safety of Uricont TU 3% was evaluated in 626 patients (210 randomized to Uricont TU 3% 56 mg/day, 214 randomized to Uricont TU 3% 84 mg/day and 202 randomized to placebo) during a randomized, placebo-controlled, double-blind, 12-week clinical efficacy and safety study. A subset of these 626 patients (N = 77) participated in the 24-week open-label safety extension that followed the placebo-controlled study. Of the 77 patients in the safety extension, 24 were randomized to placebo gel during the double-blind, placebo-controlled 12-week study. In the combined double-blind, placebo-controlled study and the open-label safety extension, a total of 441 patients were exposed to at least one dose of Uricont TU 3%. 364 patients received at least 12 weeks of Uricont TU 3% treatment and 66 patients received an additional 24 weeks of Uricont TU 3% treatment during the open-label safety extension. The study population primarily consisted of women (87%) of Caucasian descent (87%) with an average age of 59 years who had overactive bladder with urge urinary incontinence.
Table 1 lists adverse reactions (ARs), regardless of causality, that were reported in the randomized, double-blind, placebo-controlled 12-week study at an incidence greater than placebo and in greater than 3% of patients treated with Uricont TU 3%.
Overall, 672 ARs were experienced by 51.9% of patients. Majority of the ARs were mild to moderate in intensity. The AR most commonly reported was dry mouth which was experienced by a greater proportion of patients in the Uricont TU group than the placebo group (26 patients [12.1%] in the Uricont TU 84 mg group, 10 patients [5.0%] in the placebo group). Application site erythema was the next most commonly reported AR (8 patients [3.7%] in the Uricont TU 84 mg group and 2 patients [1.0%] in the placebo group). Other commonly reported ARs experienced by more patients in the Uricont TU groups compared with placebo were application site rash (7 patients [3.3%] in the Uricont TU 84 mg group and 1 patient [0.5%] in the placebo group); application site pruritus (6 patients [2.8%] in the Uricont TU 84 mg group and 1 patient [0.5%] in the placebo group). The overall rate of application site adverse reactions of any kind was 14.2% in patients receiving Uricont TU 3% as compared to 3.7% in patients receiving placebo. Other cholinergic AEs < 2% in occurrence include dry eyes and blurred vision.
There were no deaths during the study. There were no clinically meaningful changes in vital signs, laboratory values, or ECG examinations over the course of the study.
* Each patient is counted only once within each treatment, body system and preferred term. All percentages are based on number of patients in the ITT population within each treatment group as denominator.
During the 24-week open-label safety extension, the most commonly reported ARs were urinary tract infection and nasopharyngitis reported in 4 patients each (5.2%), followed by conjunctivitis and application site erythema (both occurred in 3 patients [3.9%]). One patient prematurely discontinued due to the application site erythema and pruritus (both considered to be of mild severity).
6. 2 Po s t m a r k e t ing E x perie n ce
The following adverse reactions have been identified during post approval use of GELNIQUE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Nervous System Disorders: dizziness, somnolence, confusion
Psychiatric Disorders: hallucinations
7 DRUG INTERACTIONS
No specific drug-drug interaction studies have been performed with Uricont TU 3%.
7.1 Other Anticholinergics
The concomitant use of Uricont TU 3% with other anticholinergic (antimuscarinic) agents may increase the frequency and/or severity of dry mouth, blurred vision, and other anticholinergic pharmacological effects.
8 USE IN SPECIFIC POPULATIONS
Pregnancy Category B.
There are no adequate and well-controlled studies of topical or oral Uricont TU use in pregnant women. Reproduction studies using Uricont TU chloride in the hamster, rabbit, rat, and mouse have shown no evidence of impaired fertility or harm to the fetus. The safety of Uricont TU 3% administration to women who are or who may become pregnant has not been established. Therefore, Uricont TU 3% should not be given to pregnant women unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards.
8.2 Labor and Delivery
Uricont TU 3% has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.
8.3 Nursing Mothers
It is not known whether Uricont TU is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Uricont TU 3% is administered to a nursing woman.
8.4 Pediatric Use
The safety and effectiveness of Uricont TU 3% have not been established in pediatric patients.
8.5 Geriatric Use
Of the 424 patients exposed to Uricont TU 3% in the randomized, double-blind, placebo-controlled 12-week study, 182 patients were 65 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients.
8.6 Renal Impairment
Patients with renal impairment received Uricont TU 3% during clinical trials. These trials were not designed to determine whether there were differences in safety or effectiveness in patients with or without impaired renal function.
8.7 Hepatic Impairment
Patients with hepatic impairment received Uricont TU 3% during clinical trials. These trials were not designed to determine whether there were differences in safety or effectiveness in patients with or without impaired hepatic function.
Overdosage with Uricont TU has been associated with anticholinergic effects including central nervous system excitation, flushing, fever, dehydration, cardiac arrhythmia, vomiting, exhaustion, heat sensitivity, and urinary retention. Oral ingestion of 100 mg Uricont TU chloride in association with alcohol has been reported in a 13-year-old who experienced memory loss, and in a 34-year-old who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine. Both patients recovered fully with symptomatic treatment. If overexposure occurs, monitor patients until symptoms resolve.
Uricont TU is an antispasmodic, antimuscarinic agent. Uricont TU 3% is a topical, homogeneous, very lightly to moderately opalescent, translucent colorless to slightly colored gel, without particles. The product is a hydroalcoholic gel containing 30 mg Uricont TU per gram of gel. Uricont TU 3% is available in a 0.92 gram (1 mL) unit dose that contains 28 mg Uricont TU. Uricont TU is delivered as a racemate of R- and S-isomers. Chemically, Uricont TU base is d, l (racemic) 4-(Diethylamino)-2-butynyl (±)-α-phenylcyclohexaneglycolate.
The empirical formula of Uricont TU base is C22H31NO3. Its structural formula is:
Uricont TU is widely distributed in body tissues following systemic absorption. The volume of distribution was estimated to be 193 L after intravenous administration of 5 mg Uricont TU chloride.
Uricont TU is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Metabolites include N-desethyloxybutynin (DEO), which is pharmacologically active and phenylcyclohexylglycolic acid, which is pharmacologically inactive.
Transdermal administration of Uricont TU bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyloxybutynin metabolite. Only small amounts of CYP3A4 are found in skin, limiting pre-systemic metabolism during transdermal absorption. The AUC ratio of N-desethyloxybutynin metabolite to parent compound following multiple transdermal applications is approximately 1:1 for Uricont TU 3%. The apparent half-life was approximately 30 hours.
Uricont TU undergoes extensive hepatic metabolism, with less than 0.1% of the administered dose excreted unchanged in the urine. Less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
The potential for dermal transfer of Uricont TU from a treated person to an untreated person was evaluated in a single-dose study where subjects dosed with Uricont TU 3% engaged in vigorous contact with an untreated partner for 15 minutes, either with (N = 14 couples) or without (N = 14 couples) clothing covering the application area. The untreated partners not protected by clothing demonstrated low detectable plasma concentrations of Uricont TU (mean Cmax = 0.65 ng/mL). Only one of the 14 untreated subjects participating in the clothing-to-skin contact regimen had very low measurable Uricont TU plasma concentrations (Cmax = 0.06 ng/mL) during the 24 hours following contact with treated subjects; Uricont TU was not detectable with the remaining 13 untreated subjects. Regardless of the low exposure observed in this study, patients should avoid skin-to-skin contact with partners after applying the gel.
Use of Sunscreen
The effect of sunscreen on the absorption of Uricont TU when applied 30 minutes before or 30 minutes after Uricont TU 3% application was evaluated in a single-dose randomized crossover study (N = 20). Concomitant application of sunscreen, either before or after Uricont TU 3% application, had no effect on the systemic exposure of Uricont TU.
The effect of showering on the absorption of Uricont TU was evaluated in a randomized, steady-state crossover study under conditions of no shower, or showering 1, 2 or 6 hours after Uricont TU 3% application (N = 22). The results of the study indicate that showering one hour after administration does not affect the overall systemic exposure to Uricont TU.
The effect of race on the pharmacokinetics of Uricont TU 3% has not been studied.
Available data suggest that there are no significant differences in the pharmacokinetics of Uricont TU based on geriatric status in patients following administration of Uricont TU 3% [see Use in Specific Populations (8.5) ].
The pharmacokinetics of Uricont TU and N-desethyloxybutynin following application of Uricont TU 3% has not been evaluated in individuals younger than 18 years of age [see Use in Specific Populations (8.4) ].
Available data suggest that there are no significant differences in the pharmacokinetics of Uricont TU based on gender in healthy volunteers following administration of Uricont TU 3%.
There is limited experience with the use of Uricont TU 3% in patients with renal insufficiency [see Use in Specific Populations (8.6) ].
There is limited experience with the use of Uricont TU 3% in patients with hepatic insufficiency [see Use in Specific Populations (8.7) ].
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
A 24-month study in rats at dosages of Uricont TU chloride of 20, 80, and 160 mg/kg showed no evidence of carcinogenicity. These doses are approximately 6, 25, and 50 times the maximum exposure in humans taking an oral dose, based on body surface area. Uricont TU chloride showed no increase of mutagenic activity when tested in Schizosaccharomyces pompholiciformis, Saccharomyces cerevisiae, and Salmonella typhimurium test systems. Reproduction studies with Uricont TU chloride in the mouse, rat, hamster, and rabbit showed no evidence of impaired fertility.
14 CLINICAL STUDIES
The efficacy and safety of Uricont TU 3% were evaluated in a single randomized, double-blind, placebo-controlled, multicenter 12-week study in patients with urinary frequency and urge and mixed urinary incontinence with a predominance of urge incontinence episodes. This was followed by an open-label safety extension. Key entry criteria included adults with overactive bladder (OAB) symptoms for at least 3 months who were either treatment-naïve or had demonstrated a beneficial response to anticholinergic treatment for OAB. Subjects were randomly assigned to receive 84 mg/day Uricont TU, 56 mg/day Uricont TU, or placebo. A total of 214 patients received 84 mg/day Uricont TU, 210 patients received 56 mg/day Uricont TU, and 202 patients received placebo gel. The majority of patients were Caucasian (87%) and female (87%), with a mean age of 59 years (range: 19 to 89 years). The primary efficacy endpoint was the change from baseline to week 12 in the number of urinary incontinence episodes (UIE) per week, as determined from a 3‑day patient daily diary.
Patients treated with Uricont TU 3% (84 mg) experienced a statistically significant decrease in the number of urinary incontinence episodes per week from baseline to endpoint (the primary efficacy endpoint) compared with placebo (p = 0.0445) and patients treated with the 56 mg dose did not show statistically significant efficacy. Statistically significant improvements in daily urinary frequency (p = 0.0010) and urinary void volume (p < 0.0001) were also seen with Uricont TU 3% (84 mg) relative to placebo. The mean difference from placebo for Uricont TU 3% (84 mg) was -2.3 for urinary incontinence episodes per week in a group of patients with a mean of greater than 40 incontinence episodes per week at baseline. Mean and median change from baseline in weekly incontinence episodes (primary endpoint), daily urinary frequency, and urinary void volume (secondary endpoints) between placebo and Uricont TU 3% are summarized in Table 3.
¶ Last-Observation-Carried-Forward imputation for missing data
† P-value is based on ANCOVA analysis on rank-transformed data
‡ Comparison is significant if p ≤ 0.05
§ Comparison is significant if p ≤ 0.0125, adjusting for multiplicity
16 HOW SUPPLIED/STORAGE AND HANDLING
Uricont TU 3% (oxybutynin) gel 3% is supplied in a metered-dose pump dispenser composed of an inner aluminum laminated foil liner encased in a rigid plastic bottle with a plastic cap. The nozzle of the pump dispenser is sealed by a removable cap attached to the actuator by a plastic string.
NDC 52544-041-54 100 mL (92 g) metered pump dispenser containing 90 metered 0.92 g (1 mL) pumps delivering 28 mg Uricont TU per pump actuation.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). See USP controlled room temperature. Protect from moisture and humidity.
17 PATIENT COUNSELING INFORMATION
See FDA-approved patient labeling (Patient Information)
Instructions for Use
Inform patients of the following:
Important Anticholinergic Adverse Reactions
Patients should be informed that anticholinergic (antimuscarinic) agents, such as Uricont TU 3%, may produce clinically significant adverse reactions related to anticholinergic pharmacological activity. Heat prostration (due to decreased sweating) can occur when anticholinergics such as Uricont TU 3% are used in a hot environment. Because anticholinergic (antimuscarinic) agents, such as Uricont TU 3%, may produce dizziness or blurred vision, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until this product's effects have been determined. Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic (antimuscarinic) agents such as Uricont TU 3%.
For all medical inquiries contact:
Parsippany, NJ 07054
Actavis Pharma, Inc.
Parsippany, NJ 07054 USA
Content Updated: July 2015
FDA-approved patient labeling
Uricont TU [Gel-nēk] 3%
(oxybutynin) gel 3%
Important: For use on the skin only (topical). Do not get Uricont TU 3% in or near your eyes, nose, or mouth.
Read this Patient Information carefully before you use Uricont TU 3% and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.
What is Uricont TU 3%?
Uricont TU 3% is a prescription medicine used to treat the symptoms of overactive bladder including:
It is not known if Uricont TU 3% is safe or effective in children.
Who should not use Uricont TU 3%?
Do not use Uricont TU 3% if:
Talk to your healthcare provider before taking this medicine if you have any of these conditions.
What should I tell my doctor before using Uricont TU 3%?
Before you use Uricont TU 3%, tell your doctor if you:
Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.
Uricont TU 3% may affect the way other medicines work, and other medicines may affect how Uricont TU 3% works.
Especially tell your doctor if you take:
Ask your doctor if you are not sure if your medicine is one listed above.
Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.
How should I use Uricont TU 3%?
Uricont TU 3% is for skin use only.
How to use the Uricont TU 3% pump:
You must prime the pump before you use it for the first time.
To prime the pump:
Applying Uricont TU 3%:
1. Selecting your application site:
Apply Uricont TU 3% only to 1 of the shaded areas shown in the figure below:.
2. Dispensing your dose of Uricont TU 3%:
What should I avoid while using Uricont TU 3%?
What are the possible side effects of Uricont TU 3%?
The most common side effects of Uricont TU 3% include:
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Uricont TU 3%. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
How should I store Uricont TU 3%?
Keep Uricont TU 3% and all medicines out of the reach of children.
General information about the safe and effective use of Uricont TU 3%.
Medicines are sometimes prescribed for conditions that are not mentioned in the patient information leaflet. Do not use Uricont TU 3% for a condition for which it was not prescribed. Do not give Uricont TU 3% to other people, even if they have the same symptoms you have. It may harm them.
This Patient Information leaflet summarizes the most important information about Uricont TU 3%. If you would like more information about Uricont TU 3%, talk with your doctor. You can ask your pharmacist or doctor for information about Uricont TU 3% that is written for health professionals.
For more information go to www.gelnique.com or call 1-800-272-5525.
What are the ingredients in Uricont TU 3%?
Active ingredient: Uricont TU
Inactive ingredients: diethylene glycol monoethyl ether, NF; alcohol, USP; hydroxypropyl cellulose, NF; propylene glycol, NF; butylated hydroxytoluene, NF; HCl 0.1 M, NF; and purified water, USP.
This Patient Information has been approved by the U.S. Food and Drug Administration.
For all medical inquiries contact:
Parsippany, NJ 07054
Actavis Pharma, Inc.
Parsippany, NJ 07054 USA
Content Updated: January 2013
How to use the Uricont TU 3% pump Figure A Figure B Figure C
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Arunabha Ray, MD Pharmacology